People in the News

Jul 06, 2017

Steven Kanner

Caribou Biosciences has appointed Steven Kanner as CSO. Kanner has more than 25 years of experience in drug discovery and development. He previously served in various research leadership roles at Bristol-Myers Squibb, Astex Pharmaceuticals, and Agensys/Astellas Pharma. Most recently, he served as vice president of discovery biology at Arrowhead Pharmaceuticals.

Jul 05, 2017

Chad Brown

NanoString Technologies has appointed Chad Brown senior vice president of sales and marketing. With more than 35 years of experience in life science tools and clinical diagnostics, Brown most recently served as the president and head of commercial operations for North America at Qiagen. Prior to that, Brown was with Roche Diagnostics Corporation, where he held a series of commercial leadership positions in the applied sciences and centralized diagnostics businesses. He has also held sales leadership positions in several medical device and healthcare companies, including Chiron Diagnostics, Rotech Healthcare, Apria Healthcare, and Humana.

Brown succeeds Barney Saunders, who is expected to stay with NanoString for a three-month transition period before pursuing other professional opportunities.

Jun 30, 2017

Todd Whitson

Karius has appointed Todd Whitson as chief commercial officer. Whitson joins Karius from CareDx where he served as CCO. Prior to CareDx, he served as VP of commercial operations for Ariosa Diagnostics, now part of Roche, and led sales at Genzyme Genetics, later acquired by LabCorp.

Jun 30, 2017

Ena Cratsenburg, Will Schroeder

Ginkgo Bioworks has appointed Ena Cratsenburg as chief business officer and Will Schroeder as head of metabolic engineering. Cratsenburg joins Ginkgo with over a decade of experience in business development in the biotech space. She has held positions as senior VP of the consumer sector at Intrexon, senior VP of business development at Evolva, and VP of business development for Amyris. Schroeder joins Ginkgo from Archer Daniels Midland (ADM) where he served as CP of technology. Before ADM, Schroeder spent 12 years at Cargill, overseeing strain and fermentations process development.

Jun 28, 2017

Chris van Ingen

Chris van Ingen, a former member of Bruker's board of directors, died on June 27, Bruker said in a document filed with the US Securities and Exchange Commission. van Ingen died less than a week after he told the firm that he would be retiring from the board due to medical reasons. The cause of his death was not disclosed. He had been on Bruker's board since 2012. From 2001 to 2007, van Ingen was with Agilent Technologies where he served as president of the firm's bio-analytical measurement business.

Jun 27, 2017

Brian Morra

Brian Morra has been elected executive chairman of Akonni Biosystems' board of directors. In addition to leading the board, Morra will support Akonni Founder and CEO Charles Daitch. He was a senior VP at Pacific-Sierra Research, and was a president at Veridian. 

Jun 22, 2017

Matt Tindall, Martin Reese

Matt Tindall has stepped down as CEO of Fabric Genomics, formerly Omicia, as of early May 2017. He joined the company in March 2016 when he was first appointed to the position. Martin Reese, former CSO and co-founder, has been appointed as the company's CEO. Reese has served as CEO of the company in previous years.

Jun 22, 2017

David Daly

Foundation Medicine has announced that David Daly intends to resign for personal reasons effective August 11. Daly currently serves as chief commercial officer and general manager of clinical oncology solutions for the company. No replacement has yet been named.

Jun 22, 2017

Flemming Ornskov

Waters has appointed Flemming Ornskov to its board of directors. Ornskov currently serves as CEO of Shire, where he also serves as chairman of the executive committee and as a member of its board of directors. He has also held key executive leadership positions at Bayer, Bausch & Lomb, Merck, and Novartis.

Jun 22, 2017

Mara Aspinall

OraSure Technologies has appointed Mara Aspinall to its board of directors. Aspinall currently serves as the president and CEO of Health Catalysts. She also serves as the executive chairman of GenePeeks. Prior to these positions, Aspinall served as president, CEO and global head of Roche Tissue Diagnostics. She also founded and served as CEO and director of On-Q-ity, served as president of Genzyme Genetics, served as president of the Genzyme Pharmaceuticals.

Jun 21, 2017

Philippe Goix

Avant Diagnostics has appointed Philippe Goix as president and CEO. Goix comes to Avant from Prism Health Diagnostics where he served as president, CEO, and co-founder. Before his time at Prism Health, he consulted for several healthcare companies, and has also served as president and CEO of Singulex, and president and CEO of Guava Technologies, now part of Merck Millipore.

Jun 21, 2017

Peter Meintjes

Omixon has appointed Peter Meintjes as CEO. Meintjes replaces current CEO Tim Hague who will step into a consultancy role and remains a shareholder of the company. Most recently, Meintjes served as chief commercial officer at Omixon. He joined the company in 2014.

Jun 16, 2017

Kieran Murphy

GE Healthcare has appointed Kieran Murphy as president and CEO. He succeeds John Flannery, who has been appointed CEO and chairman elect of GE. Murphy was appointed CEO of GE Healthcare Life Sciences in September 2011, and he joined GE Healthcare in 2008 from Whatman. He has also held leadership roles at Mallinckrodt, Novartis, Adprotech, ML Laboratories, and Innovata.

Jun 15, 2017

Robert Green, Natasha Frank

Veritas Genetics has appointed Robert Green and Natasha Frank to its medical and scientific advisory board. Green directs the Genomes2People research program. He also leads the first randomized trials to explore the implementation of medical sequencing in adults and newborns through the MedSeq and BabySeq projects. Frank leads research programs funded by the US National Institutes of Health, Veterans Administration, and the Department of Defense that investigate the biology of stem cells residing in human tissues and their relationship to genetic disease and cancer.

Jun 15, 2017

Sean Freeman

Molecular Assemblies has appointed Sean Freeman to its board of directors. Freeman currently serves as head of strategy and corporate development at NuVasive. He previously served as senior VP of business development for Cole-Parmer Instrument, and as head of corporate ventures and M&A at Life Technologies, which was later acquired by Thermo Fisher Scientific. He has also worked as an investment banker in Merrill Lynch's mergers & acquisitions group.

Jun 07, 2017

Heikki Lanckriet, Pilar de la Huerta, Peter Llewellyn-Davis

Sygnis has announced changes to its management team and supervisory board. Former Co-CEO Heikki Lanckriet will become sole CEO of the company and will also retain his role as CSO. Additionally, supervisory board members Maria-Hesús Sabatés Mas and Franz Wilhelm Hopp will be ending their appointment terms and will not be up for re-election. Pilar de la Huerta and Peter Llewellyn-Davis will be nominated to replace them. De la Huerta will also resign from her position as member of the management board. Llewellyn-Davis currently serves as non-executive director and chairman of the audit committee of Shield Therapeutics. He previously served as CFO and chief business officer of MediGene.

Jun 05, 2017

Joris Veltman

Joris Veltman has taken the position of director of the Institute of Genetic Medicine at Newcastle University in the UK. He previously served as a professor of translational genomics in the department of human genetics at Radboud University Medical Centre in Nijmegen in the Netherlands, with a joint appointment in the department of clinical genetics at Maastricht University Medical Centre.

Jun 02, 2017

Howard McLeod

Viviphi has appointed Howard McLeod to its precision medicine advisory board, and has named him senior research advisor in precision medicine. McLeod previously served in leadership positions at the H. Lee Moffitt Cancer Center's Department of Individualized Cancer Management. He also served as an endowed research chair in the state of Florida, professor at the University of South Florida, and serves as a 1000 Talent Scholar in China. Additionally, he has served on the FDA's committee on clinical pharmacology and on the National Institutes of Health's Human Genome Advisory Council.

Jun 01, 2017

Shelly Guyer

Invitae has appointed Shelly Guyer as its CFO, effective June 12. She will also serve as the company's principal financial officer. Invitae's current CFO Lee Bendekgey will fully transition to his new role as COO. Most recently, Guyer served as CFO of Veracyte. 

May 31, 2017

Mona Miller

The American Society of Human Genetics has appointed Mona Miller as executive director. She will be responsible for representing the ASHG on a day-to-day basis, for guiding and implementing its broad agenda in consultation with the president and board, and for interacting on an ongoing basis with society committees. Miller currently serves as the deputy executive director for programs and finance at the Society for Neuroscience. She has previously served as the society's senior director of communications and public affairs, the senior officer of public affairs at the Pew Charitable Trusts, and as communications director to former Senator Barbara Mikulski.

May 25, 2017

Saturnino Fanlo

Human Longevity has appointed Saturnino Fanlo as CFO. Fanlo will report to CEO Cynthia Collins. He joins Human Longevity from Social Finance (SoFi), where he served as president and CFO. Prior to SoFi, Fanlo held a series of high level leadership roles in various financial firms, including senior advisor at Golden Gate Capital, CEO at KKR Financial, chief information officer at KKR Asset Management, and executive VP and treasurer at Wells Fargo. He has also held positions with Goldman Sachs, Australian Capital Equity, and First Boston Corporation.

May 25, 2017

Andrea Califano

Tempus has appointed Andrea Califano to its scientific advisory board. Califano serves as the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is also the founding chair of the department of systems biology, director of the JP Sulzberger Columbia Genome Center, and associate director for bioinformatics at the Herbert Irving Comprehensive Cancer Center. Additionally, he holds appointments in the department of biochemistry and molecular biophysics and the department of biomedical informatics.

May 25, 2017

Jay Flatley

Juno Therapeutics has appointed Jay Flatley to its board of directors. He currently serves as executive chairman of Illumina and as the chair for the board of directors of Illumina's subsidiary, Helix. He also serves an advisory board member for UC San Diego's Moore Cancer Center, serves as the board of directors at Coherent and Denali, and is on the board of trustees of the Salk Institute. Previously, he served as CEO of Illumina from 1999 to 2016.  Before Illumina, he served as president and CEO of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare.

May 22, 2017

Mark Van Oene

Illumina has named Mark Van Oene chief commercial officer. He will be responsible for worldwide sales, services, and marketing and will report to CEO Francis deSouza. Van Oene previously served as Illumina's senior vice president of the Americas region and has served as interim CCO since late 2016. He joined Illumina in 2006 as regional account manager for Canada.

May 18, 2017

Don Hardison

Biotheranostics has appointed Don Hardison as CEO, succeeding Nicolas Barthelemy. Hardison originally joined Biotheranostics in July 2016 as part of its board of directors. Most recently, he served as president, CEO, and director of Good Start Genetics. He has also served as CEO of Exact Sciences and held senior leadership roles at Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham.

Pages

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.